{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:52:03Z","timestamp":1774288323435,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00432-020-03285-9","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T06:02:28Z","timestamp":1591768948000},"page":"2289-2297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"],"prefix":"10.1007","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6893-6284","authenticated-orcid":false,"given":"Ciro","family":"Franzese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Lorenzo","family":"Bonu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Comito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierina","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"3285_CR1","first-page":"v872","volume":"30","author":"GK Abou-Alfa","year":"2019","unstructured":"Abou-Alfa GK, Macarulla Mercade T, Javle M et al (2019) ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation [abstract LBA10_PR]. ESMO 30:v872\u2013v873","journal-title":"ESMO"},{"issue":"1","key":"3285_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","volume":"18","author":"N Andratschke","year":"2018","unstructured":"Andratschke N, Alheid H, Allg\u00e4uer M et al (2018) The sbrt database initiative of the German society for radiation oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):283","journal-title":"BMC Cancer"},{"key":"3285_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1748-717X-7-67","volume":"7","author":"BM Barney","year":"2012","unstructured":"Barney BM, Olivier KR, Miller RC, Haddock MG (2012) Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 7:67","journal-title":"Radiat Oncol"},{"key":"3285_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","volume":"29","author":"A Bergquist","year":"2015","unstructured":"Bergquist A, Von SE, Physician R (2015) Best practice & research clinical gastroenterology epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 29:221\u2013232","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"3285_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/PPO.0000000000000202","volume":"22","author":"RJM Correa","year":"2016","unstructured":"Correa RJM, Salama JK, Milano MT, Palma DA et al (2016) Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer J 22(4):247\u2013256","journal-title":"Cancer J"},{"issue":"1","key":"3285_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4143\/crt.2016.057","volume":"49","author":"C Franzese","year":"2017","unstructured":"Franzese C, Franceschini D, Cozzi L et al (2017) Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Res Treat 49(1):20\u201328","journal-title":"Cancer Res Treat"},{"issue":"9","key":"3285_CR7","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1002\/cam4.1707","volume":"7","author":"C Franzese","year":"2018","unstructured":"Franzese C, Zucali PA, Di Brina L et al (2018) The efficacy of stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Med 7(9):4379\u20134386","journal-title":"Cancer Med"},{"key":"3285_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden P-O, Jacobsson G, Sellstrom H, Enander L-K et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593\u2013600. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010676","journal-title":"Ann Oncol"},{"key":"3285_CR9","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672\u20131682. https:\/\/doi.org\/10.1016\/S1470-2045(16)30532-0","journal-title":"Lancet Oncol"},{"key":"3285_CR10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00268-007-9001-y","volume":"31","author":"S Hasegawa","year":"2007","unstructured":"Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y (2007) Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 31:1256\u20131263. https:\/\/doi.org\/10.1007\/s00268-007-9001-y","journal-title":"World J Surg"},{"key":"3285_CR11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA, Klimstra D, D\u2019Angelica M, DeMatteo RP et al (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689\u20131700. https:\/\/doi.org\/10.1002\/cncr.11699","journal-title":"Cancer"},{"key":"3285_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3857\/roj.2014.32.3.163","volume":"32","author":"DH Jung","year":"2014","unstructured":"Jung DH, Kim MS, Cho CK et al (2014) Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J 32:163\u2013169","journal-title":"Radiat Oncol J"},{"issue":"2","key":"3285_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.radonc.2018.02.016","volume":"127","author":"RJ Klement","year":"2018","unstructured":"Klement RJ, Hoerner-Rieber J, Adebahr S et al (2018) Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol 127(2):246\u2013252","journal-title":"Radiother Oncol"},{"issue":"15_suppl","key":"3285_CR14","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","volume":"37","author":"A Lamarca","year":"2019","unstructured":"Lamarca A, Palmer DH, Wasan HS et al (2019) ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy. J Clin Oncol 37(15_suppl):4003\u20134003","journal-title":"J Clin Oncol"},{"issue":"2","key":"3285_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","volume":"195","author":"J Lee","year":"2019","unstructured":"Lee J, Yoon WS, Koom WS et al (2019) Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 195(2):93\u2013102","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"3285_CR16","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1245\/s10434-020-08207-0","volume":"27","author":"K Morino","year":"2020","unstructured":"Morino K, Seo S, Yoh T et al (2020) Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. Ann Surg Oncol 27(6):1908\u20131917","journal-title":"Ann Surg Oncol"},{"key":"3285_CR17","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051\u20132058. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"3285_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0002-9610(56)90142-8","volume":"91","author":"CD Sawyer","year":"1956","unstructured":"Sawyer CD, Minnis JF (1956) Primary carcinoma of the gallbladder. Am J Surg 91:99\u2013105. https:\/\/doi.org\/10.1016\/0002-9610(56)90142-8","journal-title":"Am J Surg"},{"key":"3285_CR19","doi-asserted-by":"publisher","first-page":"e1911154","DOI":"10.1001\/jamanetworkopen.2019.11154","volume":"2","author":"NT Sebastian","year":"2019","unstructured":"Sebastian NT, Tan Y, Miller ED, Williams TM, Noonan AM, Hays JL et al (2019) Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma. JAMA Netw Open 2:e1911154. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11154","journal-title":"JAMA Netw Open"},{"key":"3285_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.21037\/cco.2016.10.04","volume":"5","author":"VWK Silva","year":"2016","unstructured":"Silva VWK, Askan G, Daniel TD et al (2016) Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 5:62","journal-title":"Chin Clin Oncol"},{"key":"3285_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.21873\/anticanres.11464","volume":"37","author":"T Tagawa","year":"2017","unstructured":"Tagawa T, Ito K, Fukuzawa K et al (2017) Surgical resection for pulmonary metastasis from pancreatic and biliary tract cancer. Anticancer Res 37:1413\u20131416","journal-title":"Anticancer Res"},{"key":"3285_CR22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"9","key":"3285_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L et al (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7(9):943\u2013962. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0245","journal-title":"Cancer Discov"},{"key":"3285_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.2019.37.4_suppl.187","volume":"37","author":"ZA Wainberg","year":"2019","unstructured":"Wainberg ZA, Lassen UN, Elez E, Italiano A, Curigliano G, De Braud FG et al (2019) Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. J Clin Oncol 37:187\u2013187","journal-title":"J Clin Oncol"},{"key":"3285_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","volume":"195","author":"L Wilke","year":"2019","unstructured":"Wilke L, Andratschke NBO et al (2019) ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams : Statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlentherapie Und Onkol 195:193\u2013198","journal-title":"Strahlentherapie Und Onkol"},{"key":"3285_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/archsurg.1996.01430210079015","volume":"131","author":"K Yamaguchi","year":"1996","unstructured":"Yamaguchi K, Chijiiwa K, Ichimiya H, Sada M, Kawakami K, Nishikata F et al (1996) Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch Surg 131:981\u2013985. https:\/\/doi.org\/10.1001\/archsurg.1996.01430210079015","journal-title":"Arch Surg"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03285-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:36:59Z","timestamp":1623281819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03285-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03285-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflict of interest disclosures from any authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}